A case-control study: epigenetic age acceleration in psoriasis
Archives of Dermatological Research · 2024
DOI: 10.1007/s00403-024-03075-0 ↗Kurz gefasst
Leserbrief in der Zeitschrift Archives of Dermatological Research, 2024. Verfasst von Betul Macit und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Warren Alpert Medical School, Brown University, 339 Eddy Street, Providence, RI, 02903, USA. Hauptthemen laut MEDLINE: DNA Methylation, Epigenesis, Genetic, Psoriasis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Psoriasis (PsO) is a chronic inflammatory skin condition, often accompanied by psoriatic arthritis (PsA) and linked to various comorbidities and increased mortality rates. This study aimed to explore the relationship between PsO and accelerated biological aging, specifically focusing on epigenetic DNA methylation clocks. Using a matched case-control design, 20 PsO cases were selected along with age, race, and sex-matched 20 controls without PsO from the Skin Disease Biorepository at Brown Dermatology, Inc, Providence, Rhode Island. Blood samples retrieved from both groups were analyzed for DNA methylation, and epigenetic ages were calculated using DNA methylation clocks, including Horvath, Hannum, Pheno, SkinBlood, and Grim ages. Generalized estimation equations were employed to test the differences in epigenetic and chronological ages between PsO cases and controls, as well as within various subgroups in comparison to their respective controls. There were no statistically significant differences in epigenetic ages between PsO cases and controls. However, notably, PsO cases with PsA demonstrated an accelerated PhenoAge, compared to their matched controls. This study represents a pioneering investigation into the potential link between PsO and epigenetic aging, shedding light on the possibility of accelerated epigenetic aging in PsA, possibly associated with heightened inflammatory burden. These findings emphasize the systemic impact of PsA on the aging process, prompting the need for deeper exploration into autoimmune pathways, inflammation, and epigenetic modifications underlying PsO pathogenesis and aging mechanisms. Larger-scale studies with diverse populations are imperative to discern PsO subgroups experiencing accelerated biological aging and decipher the intricate interplay between PsO, inflammation, and aging pathways.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Dermatology, Warren Alpert Medical School, Brown University, 339 Eddy Street, Providence, RI, 02903, USA.
- The Warren Alpert Medical School of Brown University, Providence, RI, USA.
- Department of Orthopedics, Rhode Island Hospital Providence, Warren Alpert Medical School of Brown University, Providence, RI, USA.
- Department of Psychiatry & Human Behavior, Alpert Medical School of Brown University, Providence, RI, USA.
- VA Center of Innovation in Long Term Services, Providence VA Medical Center, Providence, RI, USA.
- Department of Human Genetics, Gonda Research Center, David Geffen School of Medicine, Los Angeles, CA, USA.
Zitieren
APA
Macit, B., Ragi, S. D., Moseley, I., Molino, J., McGeary, J. E., Horvath, S., Qureshi, A., Reginato, A. M., & Cho, E. (2024). A case-control study: epigenetic age acceleration in psoriasis. Archives of Dermatological Research. https://doi.org/10.1007/s00403-024-03075-0
Vancouver
Macit B, Ragi SD, Moseley I, Molino J, McGeary JE, Horvath S, et al. A case-control study: epigenetic age acceleration in psoriasis. Archives of Dermatological Research. 2024. doi:10.1007/s00403-024-03075-0
BibTeX
@article{Macit2024,
author = {Macit, Betul and Ragi, Sara D and Moseley, Isabelle and Molino, Janine and McGeary, John E and Horvath, Steve and Qureshi, Abrar and Reginato, Anthony M and Cho, Eunyoung},
title = {A case-control study: epigenetic age acceleration in psoriasis},
journal = {Archives of Dermatological Research},
year = {2024},
doi = {10.1007/s00403-024-03075-0}
}
EUVIMED